Update in inclusion body myositis.

Area of Science:

• Neurology
• Immunology
• Pathology

Background:

• Inclusion body myositis (IBM) is a rare, progressive neuromuscular disorder.
• Its exact cause and pathogenesis remain poorly understood, leading to diagnostic challenges and limited treatment options.

Purpose of the Study:

• To review recent scientific advances in the natural history, etiology, treatment, and biomarkers of IBM.
• To highlight emerging diagnostic criteria and therapeutic strategies.

Main Methods:

• Literature review of recent scientific publications on inclusion body myositis.
• Analysis of studies focusing on pathogenesis, diagnostics, and therapeutic interventions.

Main Results:

• New diagnostic criteria have been proposed, acknowledging that typical pathological findings may be absent in clinically diagnosed IBM.
• The role of MRI in IBM diagnosis and monitoring is expanding, alongside increasing knowledge of pathological biomarkers.
• The identification of autoantibodies against cytosolic 5' nucleotidase 1A offers potential for earlier diagnosis and supports an autoimmune component in IBM.

Conclusions:

• IBM remains challenging to diagnose and treat, with its pathogenesis still under investigation.
• Current pharmacological treatments have shown limited efficacy, necessitating further research into disease mechanisms.
• Future research should prioritize understanding pathophysiology and developing sensitive outcome measures for clinical trials, emphasizing international collaboration for rare diseases like IBM.